Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-002136-24
    Sponsor's Protocol Code Number:0157
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2019-04-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-002136-24
    A.3Full title of the trial
    A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1473 in Subjects with Moderately-to-Severely Active Ulcerative Colitis
    Conjunto de estudios de fase IIb/III aleatorizados, controlados con placebo, doble ciego, multicéntricos, de grupos paralelos y multidosis, para evaluar la eficacia y la seguridad del tratamiento de inducción y mantenimiento con TD-1473 en pacientes con colitis ulcerosa activa de moderada a grave
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial to investigate the Efficacy and Safety of TD-1473 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
    Un ensayo clínico para investigar la Eficacia y Seguridad de TD-1473 para el Tratamiento de Colitis Ulcerosa activa de moderada a grave.
    A.3.2Name or abbreviated title of the trial where available
    Rhea: Efficacy and Safety of TD-1473 in Ulcerative Colitis
    A.4.1Sponsor's protocol code number0157
    A.5.4Other Identifiers
    Name:US INDNumber:128299
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorTheravance Biopharma Ireland Limited
    B.1.3.4CountryIreland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTheravance Biopharma Ireland Limited
    B.4.2CountryIreland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationTheravance Biopharma Ireland Limited
    B.5.2Functional name of contact pointClinical Operations - CC
    B.5.3 Address:
    B.5.3.1Street AddressConnaught House 1 Burlington Road
    B.5.3.2Town/ cityDublin 4
    B.5.3.3Post codeD04 C5Y6
    B.5.3.4CountryIreland
    B.5.4Telephone number35315532500
    B.5.5Fax number35315532501
    B.5.6E-mailIBDstudies@theravance.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTD-1473
    D.3.2Product code TD-1473
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot assigned
    D.3.9.2Current sponsor codeTD-1473
    D.3.9.3Other descriptive nameTHRX-139060
    D.3.9.4EV Substance CodeSUB192730
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTD-1473
    D.3.2Product code TD-1473
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot assigned
    D.3.9.2Current sponsor codeTD-1473
    D.3.9.3Other descriptive nameTHRX-139060
    D.3.9.4EV Substance CodeSUB192730
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTD-1473
    D.3.2Product code TD-1473
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot assigned
    D.3.9.2Current sponsor codeTD-1473
    D.3.9.3Other descriptive nameTHRX-139060
    D.3.9.4EV Substance CodeSUB192730
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCoated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Moderately-to-Severely Active Ulcerative Colitis
    Colitis Ulcerosa Activa de moderada a grave
    E.1.1.1Medical condition in easily understood language
    Ulcerative Colitis (UC)
    Colitis Ulcerosa
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10066678
    E.1.2Term Acute ulcerative colitis
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase 2b Dose-Finding Induction
    • Assess the effect of TD-1473 taken daily for 8 weeks at daily doses of 20 mg, 80 mg, and 200 mg on the change in total Mayo score
    • Assess the effect of TD-1473 on rates of clinical remission, endoscopic healing, clinical response, and mucosal (ie, histologic and endoscopic) healing
    • Upon completion, select dose(s) of TD-1473, based on safety, tolerability, and efficacy data, including exposure-response data, for continued evaluation in the Phase 3 dose-confirming Induction Study and the Phase 3 Maintenance Study

    Phase 3 Dose-Confirming Induction
    • Assess the clinical remission rates associated with TD-1473 compared to placebo treatment at Week 8
    • Assess the safety and tolerability of TD-1473 taken for up to 16 weeks

    Phase 3 Maintenance
    • Assess the clinical remission rates associated with TD-1473 compared to placebo treatment at mWeek 44
    • Assess the safety and tolerability of TD-1473 with up to 44 additional weeks of treatment
    Fase 2b inducción busqueda dosis:
    Evaluar efecto de TD-1473, administrado 8 S en dosis de 20 ,80 y 200 mg/d, sobre el valor basal en la puntuación de la clínica Mayo total.
    Evaluar efecto de TD-1473 sobre tasas de remisión clínica, de curación endoscópica, de respuesta clínica y de curación de la mucosa.
    Al finalizar, seleccionar la dosis de TD-1473 en función de los datos de seguridad, tolerabilidad y eficacia, para su evaluación en el estudio de fIII de inducción de confirmación de la dosis y de mantenimiento.

    Fase III inducción de confirmación de dosis
    Determinar tasa de remisión clínica asociada a TD-1473 en comparación con el ttmto. con placebo en la S8.
    Determinar la seguridad y tolerabilidad de TD-1473 administrado durante un 16S

    Fase III Mantenimiento
    Determinar tasa de remisión clínica asociada a TD-1473 en comparación con el ttmto. con placebo en la S44 de mmto.
    Determinar seguridad y tolerabilidad de TD-1473 con un máx. de 44S adicionales de ttmto.
    E.2.2Secondary objectives of the trial
    Phase 3 Dose-Confirming Induction
    Assess the rates of the following associated with TD-1473 compared to placebo treatment:
    • Endoscopic healing, symptomatic remission, clinical response, and mucosal healing (endoscopic and histologic) at Week 8
    • Assess at Week 16 the clinical response rate following extended induction treatment with TD-1473 in subjects who did not demonstrate clinical response at Week 8

    Phase 3 Maintenance
    Assess the rates of the following associated with TD-1473 compared to placebo treatment:
    • Clinical response, endoscopic healing, symptomatic remission, and mucosal healing at mWeek 44
    • Corticosteroid-free remission at mWeek 44
    • Maintenance of clinical remission at mWeek 44 in those who were in clinical remission at mWeek 0
    Fase 3 de inducción de confirmación de dosis
    Evaluar las siguientes tasas asociadas a TD-1473 en comparación con el tratamiento con placebo:
    •Curación endoscópica, remisión sintomática, respuesta clínica y curación de la mucosa (endoscópica e histológica) en la semana 8.
    •Evaluar en la Semana 16 la tasas de respuesta clinica siguiendo el tratamiento de inducción con TD-1473 en pacientes que no hayan demostrado respuesta clínica en la Semana 8.

    Fase 3 de Mantenimiento
    Evaluar las tasas de lo siguiente asociado al trataiento con TD-1473 comparado con placebo:
    •Remisión clínica, curación endoscópica, remisión sintómatica y curación de la mucosa S44m
    •Remisión sin corticosteroides en la S44m
    •Mantenimiento de la remisión clínica en la S44m en los pacientes que estaban en remisión en la S0m.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Optional Genetic Test
    An optional genetic testing will be performed in all subjects who agree to participate and provide their additional specific consent. The genetic blood sample should be collected at the Day 1 visit
    Test Opcional Genético
    Se realizará un test opcional genético en todos los pacientes que acepten participar y que proporcionen su consentimiento específico adicional. La muestra genética de sangre debe ser recogida en la Visita del Día 1.
    E.3Principal inclusion criteria
    1. Are male or female 18 years of age or older at Screening
    2. Has ≥ 3 months history of UC prior to screening (with involvement beyond the rectum to at least 15 cm from the anal verge)
    a. Diagnosed by sigmoidoscopy or colonoscopy AND
    b. Corroborated by histology report or documentation of histological results in a physician note. If neither is available, the subject must have a colonoscopy instead of a sigmoidoscopy at screening.
    3. Must be willing to have a sigmoidoscopy or colonoscopy at screening. Colonoscopy will be performed instead of a sigmoidoscopy at screening in the following scenarios: a. If UC diagnosis precedes screening by ≥ 8 years for pan-colitis or ≥12 years for left-sided colitis and the subject does not have documentation of a surveillance colonoscopy within 12 months prior to screening to rule out dysplasia (report must be reviewed by the investigator and included in the source documents). During colonoscopy, if chromoendoscopy or surveillance biopsies are indicated as per locally adopted guidelines, these should be performed.
    b. If UC diagnosis precedes screening by < 12 years and the subject does not have documentation of a colonoscopy within 2 years prior to screening (report must be reviewed by investigator and included in the source documents).
    c. If chromoendoscopy has to be performed or ≥ 10 biopsies are to be collected for dysplasia surveillance, either should be done after completion of a full colonoscopy to avoid chromoendoscopy dye or biopsy-related bleeding artifact from interfering with endoscopic images for central reading.
    4. Has moderately-to-severely active UC, defined as having a centrally read Mayo endoscopic sub score of ≥ 2 points based on the results of the Screening Stage 2 endoscopy and an adapted Mayo score between 4 and 9 points, inclusive, on Day 1.
    5. Is corticosteroid-dependent or had intolerance or inadequate response to any of the following: aminosalicylates, corticosteroids, immunomodulators (azathioprine or 6-mercaptopurine), or biologics (anti-TNF or anti-integrin) [Refer to Appendix 7 of the protocol]
    6. If currently receiving an oral corticosteroid, subject is eligible if:
    a. the subject has been on corticosteroids for a minimum of 4 weeks prior to Day 1 AND
    b. the dose is equivalent to or less than prednisone 25 mg/day or beclomethasone diproprionate (ie, Clipper) at 5 mg/day or budesonide 9 mg/day AND
    c. the dose is stable for at least 2 weeks prior to Screening Stage 2 visit
    7. If subject is currently receiving oral aminosalicylate (eg, mesalamine products, balsalazide, or sulfasalazine): subject is eligible provided the subject has been on it at a stable dose for ≥ 4 weeks prior to Day 1.
    8. During the Study and for 7 days after receiving the last dose of the Study drug, females of childbearing potential or men capable of fathering children must agree to use highly effective birth control measures (failure rate <1% when used consistently and correctly) or agree to abstain from sexual intercourse. Females of childbearing potential must test negative for pregnancy at screening and at Day 1 (Refer to Section 4.3 of the protocol).
    9. All male subjects must agree to refrain from semen donation during the Study and for 7 days after the last dose of Study drug.
    10. Must be able and willing to adhere to the Study visit schedule and comply with other protocol requirements.
    11. Are capable of providing informed consent, which must be obtained prior to any Study-related procedures.

    Inclusion Criteria for Extended Induction (additional 8 weeks):
    12. Did not meet criteria for clinical response by adapted Mayo score using centrally read endoscopic subscore at Week 8a

    Inclusion Criteria for Maintenance Study:
    13. Must have met the criteria for a clinical response by adapted Mayo score using centrally read endoscopic sub score during Induction at Week 8a or during Extended Induction at Week 16.
    1. Ambos sexos, de 18 años en adelante en el momento de la selección.
    2. Antecedentes ≥3 meses de CU antes de la selección (con afectación más allá del recto hasta un mínimo de 15 cm desde el margen externo del ano).
    a. Diagnosticada mediante sigmoidoscopia o colonoscopia Y
    b. confirmada mediante informe de histología o documentación de los resultados histológicos en una nota del médico. Si no se dispone de ninguno de ellos, se debe hacer una colonoscopia al paciente en lugar de una sigmoidoscopia en la selección.
    3. Disposición para hacerse una sigmoidoscopia o colonoscopia en la selección. Se efectuará una colonoscopia en la selección en lugar de una sigmoidoscopia en los siguientes casos (descritos en la Sección 6.4.1.20):
    a. Si el diagnóstico de CU es ≥8 años previo a la selección, en el caso de pancolitis, o ≥12 años previo a la selección, en el caso de colitis izquierda, y el paciente no tiene documentación de una colonoscopia de vigilancia realizada en los 12 meses anteriores a la selección para descartar una displasia (el investigador deberá revisar el informe e incluirlo en los documentos originales). Durante la colonoscopia, se deben realizar la cromoendoscopia o las biopsias de vigilancia si estas están indicadas según las guías de práctica clínica local.
    b. Si el diagnóstico de CU es <12 años previo a la selección y el paciente no tiene documentación de una colonoscopia realizada en los 2 años anteriores a la selección (el investigador deberá revisar el informe e incluirlo en los documentos originales).
    c. Si se debe realizar una cromoendoscopia o un número de biopsias ≥10 para la vigilancia de la displasia, estas deben tener lugar después de la colonoscopia completa, para evitar que el colorante de la cromoendoscopia o el artefacto de la hemorragia inducida por la biopsia interfieran en las imágenes endoscópicas de evaluación central.
    4. CU activa de moderada a grave, definida por una puntuación en el subíndice endoscópico de Mayo ≥2 puntos según la evaluación central, sobre la base de los resultados de la endoscopia efectuada en la etapa 2 de la selección, y una puntuación de la clínica Mayo adaptada comprendida entre 4 y 9 puntos, inclusive, en el día 1.
    5. Dependencia de corticosteroides o intolerancia o respuesta inadecuada a cualquiera de los siguientes tratamientos: aminosalicilatos, corticosteroides, inmunomoduladores (azatioprina o 6-mercaptopurina) o fármacos biológicos (anti-TNF o anti-integrinas) [véase el Anexo 7].
    6. Si el paciente está recibiendo actualmente un corticosteroide oral, será apto si:
    a. lo ha estado recibiendo durante un mínimo de 4 semanas antes del día 1,
    b. la dosis es equivalente o inferior a 25 mg/día de prednisona, 5 mg/día de beclometasona dipropionato (esto es, Clipper) o 9 mg/día de budesonida Y
    c. la dosis se ha mantenido durante al menos 2 semanas antes de la visita de la etapa 2 de la selección.
    7. Si el paciente está recibiendo actualmente un aminosalicilato oral (p. ej., productos con mesalacina, balsalacida o sulfasalacina): es apto si ha estado recibiendo una dosis estable durante un período ≥4 semanas antes del día 1.
    8. Durante el estudio y los 7 días posteriores a la última dosis del fármaco del estudio, las mujeres con capacidad de concebir o los hombres capaces de procrear deberán aceptar el uso de métodos anticonceptivos muy eficaces (tasa de fracaso <1 % cuando se utilizan de forma sistemática y correcta) o aceptar abstenerse de mantener relaciones sexuales. Las pacientes con capacidad de concebir deben tener un resultado negativo en una prueba de embarazo en la selección y el día 1 (véase la Sección 4.3).
    9. Todos los pacientes varones deben aceptar abstenerse de donar semen durante el estudio y los 7 días posteriores a la última dosis del fármaco del estudio.
    10 Tener la capacidad y la voluntad de cumplir con el calendario de visitas del estudio y con los demás requisitos del protocolo.
    11. Capacidad de otorgar el consentimiento informado, que se deberá obtener antes de llevarse a cabo ningún procedimiento relacionado con el estudio.

    Criterios de inclusión para la inducción ampliada (8 semanas adicionales):
    12. No haber cumplido los criterios de respuesta clínica según la puntuación de la clínica Mayo adaptada utilizando una puntuación en el subíndice endoscópico de evaluación central en la semana 8a.

    Criterios de inclusión para el estudio de mantenimiento:
    Haber cumplido los criterios de respuesta clínica según la puntuación de la clínica Mayo adaptada utilizando una puntuación en el subíndice endoscópico de evaluación central, durante el estudio de inducción en la semana 8 o durante el estudio de inducción ampliada en la semana 16.
    E.4Principal exclusion criteria
    Induction Studies and Maintenance Study Exclusion Criteria (Please refer to the protocol for the complete list of exclusion criteria)
    Subjects may not be enrolled if they:
    1. Has symptoms or signs suggestive of fulminant colitis, toxic megacolon, intestinal perforation
    2. Has primary sclerosing cholangitis (PSC)
    3. Is likely to require surgery for UC or any other type of major surgery (ie, surgical procedure requiring general anesthesia) during the Study
    4. Has had a clinically significant, as deemed by the investigator, prior intestinal resection for UC or other gastrointestinal diseases
    5. Has carried or carries a diagnosis of Crohn’s disease, microscopic colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or indeterminate colitis, or the subject has a current or past diagnosis of a fistula or abdominal abscess.
    6. Has a history of colonic mucosal dysplasia;
    7. Taken or taking any prohibited medications as listed in the protocol
    8. If subject has recently discontinued aminosalicylates or corticosteroids, these must have been stopped at minimum of 2 weeks before screening endoscopic procedure.
    9. Has been refractory to 3 biologics of ≥ 2 mechanisms of action
    10. Currently taking or has taken within 14 days prior to Day 1 any concomitant medication, herbal supplement or dietary substance (eg, grapefruit) known to be a strong inhibitor or inducer of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), or CYP450 3A4 or is a substrate of P-gp or BCRP and has a narrow therapeutic index
    11. Taking non-UC concomitant prescription medications that have started or have had a dose adjustment within 28 days prior to Day 1. Anti-diarrheal medications and probiotics are allowed only if dose has been stable for minimum of 14 days prior to Day 1.
    12. Taking over-the-counter medications or dietary supplements started or with a dose adjustment within 14 days prior to Day 1 with the exception of up to 3 times per week use of non-steroid anti-inflammatory drugs or acetaminophen used on an as needed basis, aspirin ≤ 325 mg per day for cardiovascular prophylaxis, and over the counter doses of vitamin D
    13. Subject is positive for:
    a. Hepatitis B virus (HBV) surface antigen
    b. Hepatitis B virus core antibody (unless subject has positive hepatitis B surface antibody and undetectable serum hepatitis B DNA).
    c. Hepatitis C virus (HCV) antibody unless: a) there is evidence of undetectable viral load measured twice six months apart after successful completion of treatment regimen (reviewed by Study Medical Monitor) and b) viral load during Screening is undetectable
    d. Hepatitis E
    e. Human immunodeficiency virus (HIV) antibody
    14. Subject has had a live viral vaccine within 4 weeks prior to screening and/or is unwilling or unable to avoid live viral vaccines during the Study and for 8 weeks following completion of the Study. Subject must be willing to avoid contact with any household member who has been vaccinated with a live attenuated vaccine within 2 weeks after vaccination.
    15. Has or may have untreated active or latent TB
    16. Has any of the following:
    a. An active bacterial, parasitic, fungal, mycobacterial (including atypical infection), or viral infection, except for local skin or nail bed infection, within 2 weeks prior to Day 1.
    b. Any infection requiring intravenous antibiotics within 30 days prior to screening.
    c. Any infection requiring oral antimicrobial treatment within 2 weeks prior to screening.
    d. A history of more than two episodes of herpes zoster or one or more episodes of disseminated/complicated herpes zoster (complicated: multi-dermatomal, ophthalmic, or CNS involvement or post-herpetic neuralgia) or disseminated herpes simplex.
    e. Has had a chest radiograph or equivalent chest imaging within 3 months prior to Screening or at Screening that shows an abnormality suggestive of a malignancy of current active infection, including TB, chronic lung disease or a potentially active fungal, viral, or bacterial infection.
    f. Has C. difficile or other gastrointestinal infections (eg, Salmonella, Shigella, Yersinia, Campylobacter, E. coli 0157, etc.) on stool testing or cytomegalovirus (CMV) colitis suspected on endoscopy within 30 days of Day 1.
    17. Has ever had a bone marrow transplant.
    18. Are pregnant, lactating, breastfeeding or planning to become pregnant during the Study or within 7 days after the last dose of Study Drug
    19. Has known moderate or severe hepatic impairment (eg, Child-Pugh Class B or C)
    20. Has clinically significant abnormalities in the results of laboratory evaluations at screening
    21. Has a clinically significant abnormal electrocardiogram (ECG) at screening
    22. Has known hypersensitivity to excipients or contents of the Study drug

    Exclusion Criteria for Phase 3 Maintenance Study
    Subjects who required change of UC medications or any prohibited medication to control UC symptoms during Induction Study
    Criterios de Exclusión para Estudios de Inducción y Mantenimiento
    Los pacientes no serán incluidos si:
    1 Signos o síntomas de colitis fulminante, megacolon tóxico, perforación intestinal
    2 Colangitis esclerosante primaria (CEP)
    3 Intervención quirúrgica para la CU u otra cirugía mayor durante el estudio
    4 Resección intestinal por CU u otras enfermedades gastrointestinales consideradas clínicamente significativas por el IP
    5 Tiene o ha tenido enfermedad de Crohn, colitis microscópica, colitis isquémica, colitis por radiación, enfermedad diverticular asociada a colitis o colitis indeterminada, o un diagnóstico actual o pasado de fístula o absceso abdominal
    6 Antecedentes de displasia de la mucosa colónica
    7 Haber recibido o estar recibiendo algún medicamento prohibido listado en el protocolo
    8 Ha interrumpido recientemente el ttmto con aminosalicilatos o corticosteroides, como mínimo, 2 semanas antes de la endoscopia de la selección.
    9 Resistencia a 3 fármacos biológicos con 2 o más mecanismos de acción
    10 Utilizar o haber utilizado en los 14 días previos al D1 cualquier medicamento concomitante, suplemento de fitoterapia o nutriente que sea un inhibidor o inductor potente de la gp-P, la BCRP o el CYP450 3A4, o que sea un sustrato de la gp-P o la BCRP y tenga un índice terapéutico estrecho
    11 Estar utilizando medicamentos concomitantes con prescripción médica que no sean para la CU y se hayan iniciado o se haya ajustado su dosis en los 28 días previos al D1. Se permiten los antidiarreicos y los probióticos si la dosis es estable durante al menos 14 días antes del D1
    12 Uso de medicamentos sin receta o suplementos nutricionales que se hayan iniciado o se haya ajustado su dosis en los 14 días previos al día 1, excepto el uso de antiinflamatorios no esteroideos o paracetamol hasta un máximo de 3 veces por semana según necesidad, de una cantidad de ácido acetilsalicílico ≤325 mg/d para profilaxis cardiovascular y de dosis de vitamina D
    13 El paciente presenta resultados positivos para:
    a Antígeno de superficie del VHB
    b Anticuerpos contra el antígeno central del virus de la hepatitis B (excepto si presenta anticuerpos contra el antígeno de superficie del virus de la hepatitis B y ADN del virus de la hepatitis B indetectable en suero).
    c Anticuerpos contra el VHC excepto si: a) se han obtenido pruebas de una carga viral indetectable en dos ocasiones con un intervalo de seis meses entre ellas, después de la finalización satisfactoria del tratamiento y b) la carga viral durante la selección es indetectable.
    d Hepatitis E.
    e Anticuerpos contra el VIH
    14 El paciente ha recibido una vacuna con virus vivos 4 semanas antes de la selección y/o no desea o no puede evitar recibir vacunas con virus vivos durante y 8 semanas después de la finalización del estudio. El paciente debe estar dispuesto a evitar el contacto con cualquier miembro de su hogar que haya recibido una vacuna atenuada en las 2 semanas posteriores a la vacunación.
    15 Presenta o podría presentar TB activa o latente no tratada.
    16 El paciente cumple alguno de los siguientes criterios:
    a Con infección activa bacteriana, parasitaria, micótica, micobacteriana (incluidas las infecciones atípicas) o vírica, excepto en caso de infección cutánea local o del lecho ungueal, en las 2 semanas previas al D1.
    b Con alguna infección que requiera antibióticos IV en los 30 días previos a la selección.
    c Con alguna infección que requiera tratamiento antibiótico VO en las 2 semanas previas a la selección.
    d Con antecedentes de más de dos episodios de herpes zóster o de uno o más episodios de herpes zóster diseminado/complicado o herpes simple diseminado.
    e Con una radiografía torácica o exploración torácica por la imagen equivalente en los 3 meses previos a la selección o en la selección, que muestre una alteración indicativa de neoplasia maligna o infección activa en curso, como TB, enfermedad pulmonar crónica o una infección micótica, vírica o bacteriana posiblemente activa.
    f Con infección por C. difficile u otras infecciones gastrointestinales detectadas en el análisis de heces o sospecha de colitis por CMV según lo observado en la endoscopia en los 30 días previos al D1.
    17 Trasplante de médula ósea
    18 Mujer embarazada, en período de lactancia o que tenga previsto quedarse embarazada durante el estudio o en los 7 días posteriores a la última dosis del fármaco del estudio.
    19 Con insuficiencia hepática conocida moderada o grave.
    20 Con anomalías que el investigador considere clínicamente significativas en los análisis clínicos de la visita de selección
    21 Con anomalías clínicamente significativas en el electrocardiograma (ECG) de la selección
    22 Con hipersensibilidad conocida a los excipientes o ingredientes del fármaco del estudio
    Del estudio de mantenimiento
    Pacientes que necesitaron una modificación de los medicamentos para la CU o algún medicamento prohibido para controlar los síntomas de la CU durante el estudio de inducción
    E.5 End points
    E.5.1Primary end point(s)
    Ph2b Induction Efficacy Endpoints - Change in total Mayo score from baseline at Week 8
    Ph3 Induction Efficacy Endpoints - Clinical remission by adapted Mayo score components at Week 8
    Ph3 Maintenance Efficacy Endpoints - Clinical remission by adapted Mayo score components at Week 44
    Fase2b Inducción Criterios de valoración de eficacia: Variación con respecto al valor basal en la puntuación de la clínica Mayo total en la semana 8
    Fase3 Inducción Criterios de valoración de eficacia: Remisión clínica según los componentes de la puntuación de la clínica Mayo adaptada en la semana 8
    Fase 3 Mantenimiento Criterios de valoración de eficacia: Remisión clínica según la puntuación de la clínica Mayo adaptada en la semana 44
    E.5.1.1Timepoint(s) of evaluation of this end point
    Ph2b Induction Efficacy Endpoints - Week 8
    Ph3 Induction Efficacy Endpoints - Week 8
    Ph3 Maintenance Efficacy Endpoints - Maintenance Phase Week 44
    Fase2b Inducción Criterios de valoración de eficacia: Semana 8
    Fase3 Inducción Criterios de valoración de eficacia: Semana 8
    Fase 3 Mantenimiento Criterios de valoración de eficacia Semana 44 de la Fase de Mantenimiento
    E.5.2Secondary end point(s)
    Ph2b Induction Efficacy Key Secondary Endpoints (with multiplicity control):
    • Clinical remission by adapted Mayo score components at Week 8

    Ph3 Induction Efficacy Key Secondary (with multiplicity control) Endpoints:
    • Endoscopic healing at Week 8
    • Symptomatic remission at Week 8
    • Clinical response by adapted Mayo score definition at Week 8
    • Mucosal healing at Week 8

    Ph3 Maintenance Efficacy Key Secondary (with multiplicity control) Endpoints:
    • Maintenance of clinical response by adapted Mayo score at mWeek 44
    • Endoscopic healing at mWeek 44
    • Symptomatic remission at mWeek 44
    • Corticosteroid-free remission at mWeek 44
    • Maintenance of clinical remission at mWeek 44 in those who were in clinical remission at mWeek 0
    • Mucosal healing at mWeek 44
    Fase2b Inducción Criterios de valoración de eficacia Secundarios clave (con ajuste por multiplicidad:
    • Remisión clínica según la puntuación de la clínica Mayo adaptada en la semana 8

    Fase3 Inducción Criterios de valoración de eficacia Secundarios clave (con ajuste por multiplicidad:
    • Curación endoscópica en la semana 8.
    • Remisión sintomática en la semana 8.
    • Respuesta clínica según la definición de la puntuación de la clínica Mayo adaptada en la semana 8.
    • Curación de la mucosa en la semana 8.

    Fase3 Mantenimiento Criterios de valoración de eficacia Secundarios clave (con ajuste por multiplicidad:
    • Mantenimiento de la respuesta clínica en la S44m.
    • Curación endoscópica en la S44m
    • Remisión sintomática en la S44m.
    • Remisión sin corticosteroides en la S44m.
    • Mantenimiento de la remisión clínica en la S44m en los pacientes que estaban en remisión en la S0m.
    • Curación de la mucosa en la S44m
    E.5.2.1Timepoint(s) of evaluation of this end point
    Ph2b Induction Efficacy Endpoints - Week 8
    Ph3 Induction Efficacy Endpoints - Week 8
    Ph3 Maintenance Efficacy Endpoints - Maintenance Phase Week 44
    Fase2b Inducción Criterios de valoración de eficacia: Semana 8
    Fase3 Inducción Criterios de valoración de eficacia: Semana 8
    Fase 3 Mantenimiento Criterios de valoración de eficacia Semana 44 de la Fase de Mantenimiento
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA78
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Bulgaria
    Canada
    Croatia
    France
    Georgia
    Germany
    Greece
    Hungary
    India
    Israel
    Poland
    Portugal
    Russian Federation
    Serbia
    Slovakia
    South Africa
    Spain
    Taiwan
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last subject study visit (including the 4 week follow up visit) in the Phase 3 Maintenance study.
    Ultima visita del estudio del último paciente (incluyendo la Visita de seguimiento a las 4 semanas ) en el estudio Fase 3 de Mantenimiento
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months5
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 800
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 80
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 342
    F.4.2.2In the whole clinical trial 880
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care
    Tratamiento Estándar
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-05-23
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-03-29
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2021-09-01
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 21:41:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA